Deucravacitinib is an oral, first-in-class, selective tyrosine kinase-2 (TYK-2) inhibitor and member of the Janus kinase family approved for the treatment of moderate-to-severe plaque psoriasis, and, in Japan, also for pustular and erythrodermic psoriasis.2 This evidence concerns the gene TYK2 and psoriasis vulgaris.